

GLAXOSMITHKLINE PLC  
Form 6-K  
May 01, 2019

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2019

Commission File Number 001-15170

GlaxoSmithKline plc  
(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . ☒ . . . Form 40-F . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

GlaxoSmithKline plc

Total Voting Rights and Capital

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 30 April 2019 consisted of 5,381,291,784 shares of 25 pence each ('Ordinary Shares'), of which 393,505,950 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,987,785,834. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

V A Whyte  
Company Secretary

1 May 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: May 01, 2019

By:/s/ VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for  
and on  
behalf of GlaxoSmithKline  
plc

